Post-MoCRA, the FDA still lacks enforceable composition limits for tattoo ink. A 2026 Public Health Reports policy agenda plus new bioaccessibility data show why total-content testing fails, and what studios and ink brands must do before US rules catch up to REACH.
The US is finally moving toward real tattoo ink regulation, but the 2026 policy agenda exposes a blind spot: post-MoCRA, the FDA still lacks enforceable composition limits for intradermal chemical exposure. The EU REACH framework sets hard caps on soluble metals and bans carcinogenic aromatic amines; US oversight remains stuck on contamination and sterility. New bioaccessibility data, lead exceeds limits in several inks depending on the extraction medium, proves “total content” testing is a shell game. If you run a studio, that gap is your liability.
Read the full engineering article on Poli International →
Full data, references, and the complete technical breakdown, free, no signup.
First published on poliinternational.com. This is a summary of the original engineering article.
Top comments (0)